Clinical Trials Logo

Generalized Myasthenia Gravis clinical trials

View clinical trials related to Generalized Myasthenia Gravis.

Filter by:
  • Not yet recruiting  
  • Page 1

NCT ID: NCT06392386 Not yet recruiting - Clinical trials for Generalized Myasthenia Gravis

A Study of Efgartigimod PH20 SC in Children Between 2 and Less Than 18 Years of Age With Generalized Myasthenia Gravis

Start date: May 31, 2024
Phase: Phase 3
Study type: Interventional

The purpose of this study is to measure the pharmacokinetics (PK), pharmacodynamics (PD), safety, tolerability, and immunogenicity of efgartigimod PH20 SC in pediatric participants with gMG aged 2 to <18 years. The primary goal is to confirm an appropriate dose of efgartigimod PH20 SC for pediatric patients using PK and PD results from this study. Participants will receive injections of efgartigimod PH20 SC and will be monitored for safety until the end of the study. At the end of the follow-up period, eligible participants may roll over to an open-label extension (OLE) study.

NCT ID: NCT06193889 Not yet recruiting - Myasthenia Gravis Clinical Trials

A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy, in Subjects With Refractory Generalized Myasthenia Gravis

Start date: March 2024
Phase: Phase 2
Study type: Interventional

A Study of the Anti-CD 19 Chimeric Antigen Receptor T Cell Therapy for Subjects with Myasthenia Gravis

NCT ID: NCT06149559 Not yet recruiting - Clinical trials for Generalized Myasthenia Gravis

A Study of Rozanolixizumab in Pediatric Study Participants With Moderate to Severe Generalized Myasthenia Gravis

roMyG
Start date: May 15, 2024
Phase: Phase 2/Phase 3
Study type: Interventional

The purpose of the study is to assess the safety and tolerability of subcutaneous (sc) administration of rozanolixizumab in pediatric participants aged ≥2 to <18 years with generalized Myasthenia Gravis (gMG).